New molecules reverse memory loss linked to depression, aging

memory
Credit: CC0 Public Domain

New therapeutic molecules developed at Toronto's Centre for Addiction and Mental Health (CAMH) show promise in reversing the memory loss linked to depression and aging.

These not only rapidly improve symptoms, but remarkably, also appear to renew the underlying brain impairments causing in preclinical models. These findings were presented today at the American Association for the Advancement of Science (AAAS) Annual Meeting in Washington DC.

"Currently there are no medications to treat cognitive symptoms such as memory loss that occur in depression, other mental illnesses and aging," says Dr. Etienne Sibille, Deputy Director of the Campbell Family Mental Health Research Institute at CAMH and lead scientist on the study.

What's unique and promising about these findings, in the face of many failures in for mental illness, is that the compounds are highly targeted to activate the impaired brain receptors that are causing memory loss, he says.

It took a series of studies—the most recent appearing in January 2019 in Molecular Neuropsychiatry—to reach this stage. First, Dr. Sibille and his team identified the specific impairments to brain in the GABA neurotransmitter system. Then they showed that these impairments likely caused mood and memory symptoms in depression and in aging.

New therapeutic molecules developed by Dr. Etienne Sibille at Toronto's Centre for Addiction and Mental Health (CAMH) show promise in reversing the memory loss linked to depression and aging. These molecules not only rapidly improve symptoms, but remarkably, also appear to renew the underlying brain impairments causing memory loss in preclinical models. Credit: Patrick Callan, CAMH

The new small molecules were invented to bind to and activate this receptor target. The idea was that they would exert a by "fixing" the impairment, resulting in an improvement in symptoms. The molecules are chemical tweaks of benzodiazepines, a class of anti-anxiety and sedative medications that also activate the GABA system, but are not highly targeted.

A single dose of these new molecules was administered in preclinical models of stress-induced memory loss. Thirty minutes later, memory performance returned to normal levels, an experiment that was reproduced more than 15 times. In another experiment involving preclinical models of aging, memory declines were rapidly reversed and performance increased to 80 per cent after administration, essentially reaching levels seen in youth or earlier stages of adulthood. This improvement lasted over two months with daily treatment.

New therapeutic molecules developed by Dr. Etienne Sibille at Toronto's Centre for Addiction and Mental Health (CAMH) show promise in reversing the memory loss linked to depression and aging. These molecules not only rapidly improve symptoms, but remarkably, also appear to renew the underlying brain impairments causing memory loss in preclinical models. Credit: Patrick Callan, CAMH

"The aged cells regrew to appear the same as young brain cells, showing that our novel molecules can modify the brain in addition to improving symptoms," says Dr. Sibille. He expects to start testing the molecules in clinical research in two years. "We've shown that our molecules enter the brain, are safe, activate the target cells and reverse the cognitive deficit of memory loss."

If successful, the potential applications are broad. Not only is there a lack of treatment for cognitive deficits in , but the brain improvements suggest the molecules could help to prevent the loss at the beginning of Alzheimer's disease, potentially delaying its onset.


Explore further

Being unaware of memory loss predicts Alzheimer's disease, new study shows

More information: Molecular Neuropsychiatry, www.karger.com/Article/Abstract/496086
Citation: New molecules reverse memory loss linked to depression, aging (2019, February 14) retrieved 20 August 2019 from https://medicalxpress.com/news/2019-02-molecules-reverse-memory-loss-linked.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
42 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more